Blis trims ebitda guidance on higher costs

Blis trims ebitda guidance on higher costs
Staff reporters
Strong covid-related sales into the US saw probiotic manufacturer Blis Technologies push earnings before interest, tax, depreciation and amortisation up 12 percent to $1.3 million for the December quarter, but it expects higher product investment to cut into full year-earnings for 2021.The Dunedin-based firm has now set its sights lower for ebitda to between $1 million and $1.3 million, compared to prior guidance for the 2021 year of closer to $2.1 million.In its quarterly review, chief executive Brian Watson said the third quarter had seen str...